Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies.

BACKGROUND

Given similarities in the mediators of medication allergy (MA) and tissue response to radiotherapy, we assessed whether outcomes following prostate radiotherapy differ in patients with MAs.

METHODS

A total 587 men with known MA history and nonmetastatic prostate cancer underwent radiotherapy from 1989 to 2006. Clinicopathologic and treatment variables were analyzed for association with freedom from biochemical failure (FFBF) and late treatment-related, physician-defined Radiation Therapy Oncology Group gastrointestinal (GI) and genitourinary (GU) toxicity. Covariates identified on univariate analysis for toxicity and disease control were examined on multivariable analysis. All statistical tests were 2-sided, and a less than .05 was considered statistically significant.

RESULTS

A total of 155 of 587 men (26.4%) had 1 or more MAs, most commonly to penicillin (n = 71), sulfa (n = 35), and aspirin or nonsteroidal antiinflammatory drugs (n = 28). On univariate analysis, men with MAs had superior 10-y FFBF (71.5% vs 63.5%, .02) and higher incidence of late GI grade 2 or higher (G2+; 20.6% vs 13.2%, .04) and grade 3 or higher (G3+; 7.5% vs 3.9%, .08) as well as late GU G2+ (42.5% vs 33.2%, .04) and G3+ (7.5% vs 3.0%, .02) toxicity than men without MAs. On multivariable analysis, MA history remained a statistically significant predictor of FFBF (hazard ratio [HR] = 0.64, 95% confidence interval [CI] = 0.43 to 0.93, .02), late G2+ GI (HR = 1.76, 95% CI = 1.06 to 2.90, .03), and G3+ GU (HR = 2.69, 95% CI = 1.16 to 6.27, .02) toxicity after controlling for corresponding covariates in each model.

CONCLUSIONS

Men with MAs had improved FFBF and increased treatment-related toxicity following radiotherapy for prostate cancer. MA history could be a relevant consideration in the management of men with localized prostate cancer.